Apr 17, 2012 | PR-inside.com
Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.
Basilea Pharmaceutica AG / Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.
Basilea's U.S. phase III Handel study with investigational...
Basilea Pharmaceutica AG / Basilea's U.S. phase III HANDEL study with investigational compound oral alitretinoin meets study endpoints .
Basilea Reports 2011 Financials With Better Than Expected Operating Results
Basilea Pharmaceutica AG / Basilea reports 2011 financials with better than expected operating results .
Basilea to file application for marketing authorization of...
Basel, Switzerland, January 5, 2012 - Basilea Pharmaceutica Ltd. today announced that it will apply in the second half of 2012 for approval of its antibiotic ceftobiprole in Europe.
Keratitis-Ichthyosis-Deafness Syndrome: Response to Alitretinoin and...
Report of Case We describe a 37-year-old white woman with keratitis-ichthyosis-deafness syndrome .
Also on Topix